Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian
immuno-oncology company, will release its fourth quarter and second half 2022
results on Thursday, 16 February 2023 at 8am CEST. The results will be presented
in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein
at 2:30pm CEST. 

We encourage you to send us questions in advance, to be addressed during the Q&A
session. Please send your questions in an email to post@lytixbiopharma.com. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here:  https://forms.office.com/e/q06xRZSrBV

A recording of the presentation will be made available on
https://www.lytixbiopharma.com/investors/overview.html after the presentation.


For more information, please contact: 
* Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
* Ole Peter Nordby, Head of IR & Communication Manager:
ole.peter.nordby@lytixbiopharma.com


Lytix in brief: Based in Oslo, Norway, Lytix is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic molecule representing a new
and superior therapeutic principle to boost anti-cancer immunity, with the
potential to be the ideal combination partner with other types of
immunotherapies. LTX-315 targets cancer cells and disintegrates their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens and potent immunostimulants. This mode of action allows
cytotoxic T cells to recognize, infiltrate and attack cancer cells.